Home » J&J’s Codman Neuro Recall Upgraded to High Risk Class I
J&J’s Codman Neuro Recall Upgraded to High Risk Class I
Codman Neuro, a division of Johnson & Johnson subsidiary DePuy Synthes, said the FDA labeled its Trufill n-BCA liquid embolic system recall as Class I, the federal watchdog agency’s highest-risk classification.
MassDevice
MassDevice
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May